Business
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
HYDERABAD, India & REYKJAVIK, Iceland, March 18, 2025--Alvotech and Dr. Reddy’s announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®.
About this update from Dr. Reddy's Laboratories Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":812,"height":250,"url":"https://media.zenfs.com/en/business-wire.com/eb2695aef9d8d7e045bcc898dbf231f2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Tf0jQSJUwyVjSjL2mwKRwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI5NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eb2695aef9d8d7e045bcc898dbf231f2","width":812,"height":250},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.xkb3ebD1cjrakjqk6QSAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MjQ7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/eb2695aef9d8d7e045bcc898dbf231f2","width":812,"height":250}},"lazy":false},{"type":"text","content":"HYDERABAD, India & REYKJAVIK, Iceland, March 18, 2025--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy’s") and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, developed by Alvotech, a proposed biosimilar of Prolia® (denosumab) and Xgeva® (denosumab).","length":625,"tagName":"p"},{"type":"text","content":""The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.," said Milan Kalawadia, Chief Executive Officer, Dr. Reddy’s North America.","length":272,"tagName":"p"},{"type":"text","content":""This milestone marks an important step in our mission to improve patient lives by expanding access to affordable and quality biologic medicines. We look forward to being able to serve the large population of patients requiring treatment for osteoporosis and other diseases of the bone," said Joseph McClellan, Chief Scientific Officer for Alvotech.","length":359,"tagName":"p"},{"type":"text","content":"Prolia® is a prescription biologic medicine used to treat osteoporosis in women after menopause who are at high risk for bone fracture or cannot use another osteoporosis medicine or other osteoporosis med...